AstraZeneca's Gefulimab Nanobody Hits Phase III Endpoints

TL;DR

AZN's Gefulimab nanobody successful in Phase III for lung cancer. Big win for oncology pipeline.

AI Summary

AstraZeneca PLC announced on July 24, 2025, that its Gefulimab nanobody met the primary endpoints in a Phase III trial. The trial evaluated Gefulilimab in combination with chemotherapy for the treatment of patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC). Further details on the specific endpoints and results were not provided in this filing.

Why It Matters

Positive Phase III results for Gefulimab could lead to a new treatment option for non-small cell lung cancer, potentially impacting patient outcomes and AstraZeneca's market share in oncology.

Risk Assessment

Risk Level: low — This filing is an informational report of a positive clinical trial outcome, not a financial transaction or regulatory action that typically carries higher risk.

Key Players & Entities

• AstraZeneca PLC (company) — Registrant
• Gefululimab (drug) — Investigational nanobody
• non-small cell lung cancer (NSCLC) (disease) — Indication for Gefululimab
• July 2025 (date) — Reporting period
• 20250724 (date) — Filing date

FAQ

From the Filing

0001654954-25-008413.txt : 20250724 0001654954-25-008413.hdr.sgml : 20250724 20250724130949 ACCESSION NUMBER: 0001654954-25-008413 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250724 FILED AS OF DATE: 20250724 DATE AS OF CHANGE: 20250724 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251145770 BUSINESS ADDRESS: STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a3269s.htm GEFURULIMAB NANOBODY MET PHASE III ENDPOINTS a3269s FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of July 2025   Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________     AstraZeneca PLC   INDEX TO EXHIBITS 1. Gefurulimab nanobody met Phase III endpoints     24 July 2025   Gefurulimab dual-binding nanobody demonstrated statistically significant and clinically meaningful improvement in functional activities of daily living in adults with generalised myasthenia gravis in PREVAIL Phase III trial   Once-weekly self-administered subcutaneous C5 inhibitor showed statistically significant and clinically meaningful reduction in disease severity   at week 26       Positive high-level results from a global,   randomised, double-blind, placebo-controlled   Phase III trial in adults with anti-acetylcholine receptor (AChR) antibody-positive (Ab+) generalised myasthenia gravis (gMG) showed that gefurulimab met its primary and all secondary endpoints. Data demonstrated a statistically significant and clinically meaningful improvement from baseline in   Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at week 26 compared to placebo.   gMG is a rare, debilitating, chronic, autoimmune neuromuscular disease that leads to a loss of muscle function and severe weakness. 1  Those living with gMG may initially experience slurred speech, double vision, droopy eyelids and weakness, with symptoms becoming more severe as the disease progresses, including extreme fatigue, difficulty swallowing, choking and respiratory failure. 2,3   Kelly Gwathmey, MD, Associate Professor of Neurology, Chief of Neuromuscular Division, Virginia Commonwealth University, Richmond, VA, Vice Chair of the MGFA Medical & Scientific Advisory Council and principal